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Abstract
Background and aim: Polysaccharide from fuzi (FPS), a Chinese herbal medicine extract, has been demonstrated
to exert lipid lowering affects. In this study we examined potential mechanisms underlying this affect, specifically
alterations in expression of the LDL-receptor (LDL-R), 3-hydroxy-3-methyl glutaryl (HMG)-CoA reductase and
cytochrome P450 7a-1 (CYP7a-1), using a rat model of hypercholesterolemia.
Methods and results: Male rats were fed either a normal or high cholesterol (HC) diet for two-weeks. Half of the
rats on the HC diet were orally gavaged with FPS (224 mg/kg, 448 mg/kg or 896 mg/kg diet) daily. Serum lipid
levels were quantified at end of the study period as were liver levels of LDL-R protein and mRNA expression of
CYP7a-1 and HMG-CoA. Serum cholesterol and LDL-C concentrations were significantly elevated from control in
HC rats, but not in those treated with FPS (P < 0.05). LDL-R expression was significantly decreased in the HC group
compared to control (P < 0.05), but significantly increased in the FPS group (P < 0.05). HMG-CoA mRNA levels
were significantly increased in the HC group compared both other groups (P < 0.05), while CYP7a-1 expression
was significantly higher in the FPS group compared to both other groups (P < 0.05).
Conclusion: These findings suggest that the cholesterol lowering effect of FPS in hypercholesteremic rats is
caused at least in part by increased hepatic LDL-R and CYP7a-1 expression and decreased HMG-CoA expression.
Further study is needed to determine precisely where and how FPS exerts these effects. FPS offers potential as a
therapeutic agent for the treatment of hypercholesterolemia.
Introduction
Hypercholesterolemia is an important risk factor for
atherosclerosis and consequent cardiovascular and cere-
brovascular disease. Increased circulating levels of low-
density lipoprotein (LDL) underlie the development of
atherosclerosis [1,2]. Statins have been shown to effec-
tively lower LDL levels and reduce both mortality and
morbidity associated with coronary heart disease by 30%
[3]. However, as noted Steinberg and colleagues in a
recent review [4], this still leaves a significant percentage
of individuals for whom statin therapy will not prevent
the occurrence of adverse events. There is an obvious
need for more efficacious and alternative treatment
options.
Many Chinese herbal medicines contain polysacchar-
ides which can exert a wide range of pharmacological
effects, including lipid lowering [5-10]. One such poly-
saccharide has been extracted from Radix Aconiti Car-
michaeli Praeparata in our laboratory, designated as
polysaccharide from fuzi (FPS). In previous investiga-
tions, we found have that FPS has both immunomodu-
latory and hypoglycemic effects [11-13]. Specifically we
noted that rats treated with FPS exhibited significantly
reduced cyclophosphamide-related bone marrow sup-
pression, an increased number of peripheral white
blood cells, reduced oxidative damage in the bone
marrow and increased gene and protein expression of
the antioxidant enzyme Cu-Zn superoxide dismutase
[14,15]. Apoptosis in bone marrow cells was also
inhibited (as indicated by decreased caspase-9 and -3
levels) via increased expression of the anti-apoptotic
Bcl-2 gene and decreased expression of the pro-apop-
totic BAX gene. Further to this, after two weeks of
treatment with FPS (160 mg/kg), elevations in serum
triglyceride, cholesterol and LDL levels induced by
high-fat diet feeding were significantly reduced. In this
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same study, the cholesterol and LDL lowering effects
of FPS were similar to that of fluvastatin. The trigly-
ceride lowering effect, however, was increased follow-
ing FPS compared to fluvastatin treatment. Given its
reported lipid-lowering and immunomodulatory effects,
FPS may be of potential use as an anti-atherosclerotic
agent.
The mechanisms underlying the lipid lowering effects
of FPS have not been determined. It is essential that
these mechanisms be determined to facilitate further
development of this agent as a potential therapeutic.
Hence the aim of the present study was to investigate
the mechanisms underlying FPS-induced hypolipidemia
using a rat model of dietart-induced hypercholesterole-
mia. Specifically we examined the possibility that altered
expression of three key players in hepatic lipid metabo-
lism, the LDL-receptor (LDL-R), 3-hydroxy-3-methyl
glutaryl (HMG)-CoA reductase and cytochrome P450




Fifty male Wistar rats, aged 8-12 weeks and weighing
100 ± 10 g, provided by the Animal Centre of Sun Yat-
Sen University were used. Rats were housed in a tem-
perature controlled environment, with a fixed light/dark
cycle. This study was approved by the institutional inter-
nal review board.
The rats were randomly divided into one of the five
following groups: control; high cholesterol; high choles-
terol + 224 mg/kg FPS; high cholesterol + 448 mg/kg
FPS; high cholesterol + 869 mg/kg FPS. The dose of
FPS for each treatment group was decided according to
the results of our preliminary study. Hence there were
10 rats in each experimental group.
Experimental procedure
Hypercholesterolemia was induced by feeding the rats a
diet high in cholesterol for a period of 14 days. The diet
contained 2% cholesterol (Probe Biological Technology
Ltd. Beijing, China), 0.5% bile salt (AOBO Star Biotech-
nology Ltd., Beijing, China) and a standard chow mix
[16,17]. Rats in the control group were fed a standard
laboratory diet, normal in cholesterol.
Rats in the intervention groups were orally gavaged
with the appropriate dose of FPS in a volume of 1 ml.
Rats in the control and high cholesterol group were
gavaged daily with isotonic saline (1 ml).
FPS was extracted in our laboratory as previously
described [11].
Body weight, food intake and fecal excretion were
measured throughout the study period. Food intake and
fecal excretion were determined over 24 h in each case.
Fecal samples from the final 3 days of the study were
further processed to determine bile acid content.
At the completion of the study, each rat was anaesthe-
tized with intraperitoneal sodium pentobarbital (40 mg/
kg; Shanghai Chemical Reagent Company, Beijing,
China) and an arterial blood sample was collected. They
were then sacrified by cervical dislocation and the liver
was then rapidly removed, washed in saline, dried on fil-
ter paper and divided into two parts. One part was fixed
in 10% formalin and then paraffin-embedded for hema-
toxylin and eosin staining and immunohistochemistry.
The other half was immediately snap-frozen in liquid
nitrogen and stored at -80°C for later assessment of
HMG-CoA reductase and CYP7a-1 mRNA levels by
real-time PCR.
Real-time PCR [18,19]
Total mRNA was isolated by Trizol reagent according to
the procedure of the supplier (Invitrogen, USA). Real-
time PCR was performed using SYBR green (Roche,
USA) and standard procedures to assess the mRNA
expression of HMG-CoA reductase and CYP7a-1 in
liver samples obtained from each rat. An Applied Bio-
systems 7500 real-time PCR machine was used (Applied
Biosystems, USA).
The HMG-CoA reductase primer pairs were:
5’-CTT GAC GCT CTG GTG GAA TG-3’
and 5’-AGT TGG AAG CAC GGA CATA-3’
The amplified HMG-CoA fragment was 106 bp, while
the reaction parameters were as follows: 10 cycles of 94°
C denaturation for 3 min; 94°C denaturation for 60 sec
and 55°C annealing for 45 sec.
The CYP7a-1 primer pairs were:
5’-ATG ACC TGC CGG TAC TAG ACA-3’
and 5’-TGA AGT CCT CCT TAG CTG TGC-3’.
The amplified CYP7a-1 fragment was 90 bp, while the
reaction parameters were as follows: 30 cycles of 94°C
denaturation for 45 sec and 55°C annealing for 30 sec.
Quantification of bile acid
Fecal samples were dried at 56°C until the weight
remained constant. Fifty mg from each sample was
added to distilled water (1 ml) and homogenized. Four
ml of methanol was then added and the sample was
blended in an ultrasonic oven for 1 h, stored at room
temperature until the temperature decreased and then
centrifuged at 2500 rpm for 10 min. The supernatant
(0.5 ml) was removed and mixed with ethanol (1.75
ml), 6% barium hydroxide (0.1 ml) and 10% zinc sul-
fate (0.05 ml). The sample was then centrifuged at
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2500 rpm for a further 10 min and the proteins and
pigment in the precipitant removed. A volume of
supernatant (0.2 ml) was removed, placed in a glass
tube, steam-dried, reconstituted with 0.1 ml of distilled
water, 3.9 ml of a chloroform/methanol mixture (2:1)
and Folch solution (0.88 ml), mixed thoroughly and
left for stratification. The supernatant containing total
bile acid (1.8 ml) was withdrawn into a 5 ml tube. The
extraction procedure was repeated three times on the
remaining solution. Each time, 1 ml of resultant super-
natant was removed. Methanol (0.2 ml) was added to
the combined volume of supernatant; bringing the
total volume to 5 ml. 0.5 ml of this mixture was
steam-dried in a glass tube, after which 2 ml of phos-
phomolybdate acid reagent was added. The solution
was then maintained at 80°C in a water bath for 60
minutes, before being cooled in ice water for 5 min to
terminate the reaction. Diluent (2 ml) was then added,
the solution mixed and absorbance at 690 nm deter-
mined using a spectrophotometer.
Western blotting [20]
Frozen liver was homogenized and centrifuged. Superna-
tant was collected and protein concentration was deter-
mined using a Bio-Rad kit (Bio-Rad Laboratories). Liver
extracts (100 ug) were analyzed by Western blot analysis
with antibody against rat LDL-R antibody (1:800, Santa
Cruze, USA). Blots were reblotted with antibody against
GAPDH for a loading control.
Quantification of serum total cholesterol, triglyceride and
high- and low-density lipoprotein concentrations
Total cholesterol, triglyceride, HDL-C and LDL-C serum
concentrations were determined using kit methods fol-
lowing the instructions provided (Shanghai Rongsheng
Biotechnology Company, Shanghai, China).
Statistical analyses
Data were compared between groups by one-way ana-
lysis of variance. When a significant between groups
difference was apparent, multiple comparisons of
means were performed using the Bonferroni procedure
with type-I error adjustment. Data are presented as
means ± standard SD. All statistical assessments were
two-sided and evaluated at the 0.05 level of significant
difference. Statistical analyses were performed using
SPSS 15.0 statistical software (SPSS Inc, Chicago, IL).
Results
Table 1 summarizes the lipid profiles of rats in each of
the five groups. There were significant differences in
serum cholesterol and LDL-C levels between the five
groups (P < 0.05). Serum cholesterol and LDL-C levels
in the HC group were significantly higher than those in
the control group (P < 0.05). Concentrations of serum
cholesterol and LDL-C were significantly lower in each
of the FPS groups compared to the HC group (P <
0.05).
Figure 1 summarizes the changes in body weight over
the study period for the different groups. For each, body
weight increased significantly over the course of the
study period (P < 0.001), however there were no between
group differences. There were no significant within or
between group differences in food intake or feces dry
weight over the study duration (Figures 2 and 3).
There was a significant difference in the content of
fecal bile acid among the three 3 groups (Figure 4; P <
0.001). Bile acid content was significantly higher in the
HC group compared to control group (P < 0.001), while
levels were significantly higher in the FPS group com-
pared to both other groups (P < 0.001).
Figure 5 summarizes liver LDL-R protein expression
for each group of rats as determined by Western blot-
ting. Hepatic LDL-R protein expression was significantly
decreased in the HC group compared to both other
groups (P < 0.001), while expression levels were signifi-
cantly higher in the FPS group compared to the control
group (P < 0.001).
The hepatic mRNA expression levels of HMG-CoA
reductase and CYP7a-1 as determined by real time-PCR












Cholesterol (mmol/L) 1.33 ± 0.19 2.89 ± 0.48† 2.20 ± 0.38†‡ 1.91 ± 0.46‡ 1.93 ± 0.37‡ <0.001*
Triglyceride (mmol/L) 0.79 ± 0.21 0.85 ± 0.33 0.88 ± 0.38 0.76 ± 0.36 0.87 ± 0.35 0.942
LDL-C (mmol/L) 0.79 ± 0.07 1.97 ± 0.46† 1.20 ± 0.15†‡ 1.13 ± 0.10‡ 1.27 ± 0.21†‡ <0.001*
HDL-C (mmol/L) 1.11 ± 0.17 1.22 ± 0.27 1.19 ± 0.24 1.11 ± 0.26 1.15 ± 0.33 0.830
Data are presented as the mean ± standard deviation.
HC = high cholesterol; FPS = Polysaccharide from Fuzi; LDL = low-density lipoprotein; HDL = high-density lipoprotein.
^P-values are based on analysis of variance testing.
* Indicates an overall significant difference (P < 0.05).
† Indicates a statistically significant difference between the highlighted treatment group and the control group (P < 0.05).
‡Indicates a statistically significant difference between the highlighted treatment group and the HC group (P < 0.05).
Pair-wise multiple comparisons between groups were determined using Bonferroni’s test with a = 0.007 adjustment.
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are summarized in Table 2. Significant overall differ-
ences were apparent for both enzymes (P < 0.001).
HMG-CoA reductase mRNA expression was signifi-
cantly higher in the HC group compared to both the
control and FPS groups (P < 0.05). There was no signifi-
cant difference between the FPS and control group for
this variable. CYP7a-1 mRNA levels were significantly
higher in the FPS group compared to both the HC and
control groups (P < 0.05).
Discussion
In this study we utilized a rat model of hypocholestero-
lemia to investigate the mechanisms underlying the
lipid-lower effects of FPS, a Chinese herbal medicine
extract. In the face of hypocholesterolemia, we found
that treatment with FPS not only significantly reduced
serum LDL and cholesterol concentrations, but also
increased mRNA expression of HMG-CoA reductase
and CYP7a-1 in the liver. Further to this, LDL-R
expression levels were markedly decreased.
The number and activity of LDL-Rs are important fac-
tors that influence the metabolism of LDL [21,22]. This
receptor internalizes LDL, thus lowering plasma LDL
and cholesterol concentrations [16]. Previous studies
Figure 1 Summary of body weight changes over the study
period for each group of rats. Control rats were fed a normal
diet. Rats in the high cholesterol (HC) group were fed a high
cholesterol diet. Rats in the FPS group were fed the high
cholesterol diet and were treated with FPS (224 mg/kg) daily. All
rats (regardless of group) gained significant weight over the study
period (P < 0.05).
Figure 2 Summary of 24 h food intake over the study period
for each group of rats. Control rats were fed a normal diet. Rats in
the high cholesterol (HC) group were fed a high cholesterol diet.
Rats in the FPS group were fed the same high cholesterol diet and
were treated with FPS (224 mg/kg) daily.
Figure 3 Summary of 24 h fecal dry weight over the study
period for each group of rats. Control rats were fed a normal
diet. Rats in the high cholesterol (HC) group were fed a high
cholesterol diet. Rats in the FPS group were fed the same high
cholesterol diet and were treated with FPS (224 mg/kg) daily.
Figure 4 Summary of fecal bile acid content over the last three
days of the study period for each group of rats. Control rats
were fed a normal diet. Rats in the high cholesterol (HC) group
were fed a high cholesterol diet. Rats in the FPS group were fed
the same high cholesterol diet and were treated with FPS (224 mg/
kg) daily. * indicates a statistically significant between groups
difference (P < 0.05).
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have shown that many hypolipidemic drugs affect LDL-
R expression [23,24]. Further to this, there are a sub-
stantial number of reports indicating that various cho-
lesterol-lowering Chinese herbal medicines also
influence LDL-R expression [23]. In the present study,
LDL-R immunohistochemical and Western blot analysis
was performed on liver tissue obtained from rats fed a
high cholesterol diet. We found that the expression of
LDL-R was significantly decreased in tissue obtained
from rats fed a high cholesterol diet compared to rats
fed a normal diet. In contrast, rats fed the high choles-
terol diet and treated with FPS exhibited no such
decrease in LDL-R expression; rather the levels were sig-
nificantly increased from those in control rats. Taken
together, these findings lead us to suggest that one of
the mechanisms through which FPS promotes choles-
terol lowering is by inducing LDL-R receptor expression
and density, thus enhancing the transfer, conversion and
removal of LDL (and cholesterol) from the circulation.
HMG-CoA reductase is the rate-limiting enzyme of
the mevalonate pathway, a key pathway of cholesterol
synthesis [25]. Indeed inhibition of this enzyme in the
liver by statins results in decreased cholesterol synthesis,
increased LDL-R synthesis and consequent decreases in
circulating levels of LDL and cholesterol [26,27]. In the
present study, we found that the significantly increased
hepatic HMG-CoA reductase mRNA expression levels
in rats fed a high cholesterol diet were normalized by
treatment with FPS. Indeed HGM-CoA reductase levels
were lower (but not significantly so) in FPS treated rats
compared to control rats. Hence it would appear that,
similar to statins, the cholesterol lowering effect of FPS
may be in part due to inhibition of hepatic HMG-CoA
reductase expression. It is unclear precisely how this
inhibition may be mediated (direct or upstream).
Further studies are needed to determine this.
Our finding that rats fed a high cholesterol diet exhib-
ited increased HMG-CoA reductase expression contrasts
with a previous report suggesting that increased choles-
terol absorption associated with a high fat diet leads to
increased free cholesterol levels in hepatocytes and con-
sequent inhibition of HMG-CoA reductase expression.
It is unclear why HMG-CoA mRNA expression was
increased in our study.
One of the primary sites of cholesterol metabolism is
the liver, where it is converted into bile acid and subse-
quently excreted in feces. The rate limiting enzyme of
this process is CYP7a-1. Indeed increased CYP7a-1 has
been demonstrated to hasten the rate of conversion of
cholesterol to bile acids in hepatocytes [27,28]. In this
study we found that the hepatic mRNA expression levels
of CYP7a-1 were significantly elevated in rats treated
with FPS as compared to those in the control and high
cholesterol groups. This finding indicates that FPS can
induce expression of the CYP7a-1 gene. A further test
with Western blotting also revealed that the FPS stimu-
lated CYP7a-1 protein expression. In keeping with this
finding, the levels of bile acid in fecal samples were
Figure 5 Summary of hepatic low-density lipoprotein receptor
(LDL-R) expression levels for each group of rats as determined
at study completion by Western blotting. Control rats were fed a
normal diet. Rats in the high cholesterol (HC) group were fed a high
cholesterol diet. Rats in the FPS group were fed the same high
cholesterol diet and were treated with FPS (224 mg/kg) daily. *
indicates a statistically significant between groups difference (P < 0.05).
Table 2 Summary of hepatic HMG-CoA reductase and CYP7a-1 mRNA expression levels in rats fed a high cholesterol








HMG-CoA reductase 1.29 ± 0.36 4.17 ± 1.83† 0.73 ± 0.39‡ <0.001*
CYP7a-1 0.78 ± 0.43 0.74 ± 0.49 4.08 ± 1.58†‡ <0.001*
Data are presented as the mean ± standard deviation.
HC = high cholesterol; FPS = Polysaccharide from Fuzi;
^P-values are based on analysis of variance testing.
* Indicates an overall significant difference (P < 0.05).
† Indicates a statistically significant difference between the highlighted treatment group and the control group (P < 0.05).
‡Indicates a statistically significant difference between the highlighted treatment group and the HC group (P < 0.05).
Pair-wise multiple comparisons between groups were determined using Bonferroni’s test with a = 0.017 adjustment.
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markedly elevated in rats treated with FPS, demonstrat-
ing that the increased CYP7a-1 expression resulted in
heightened cholesterol metabolism. The mechanism(s)
through which FPS influences CYP7a-1 expression war-
rants further investigation.
In this study we have explored several potential mechan-
isms through which FPS lowers systemic cholesterol levels
using a rat model of hypercholesterolemia. We report for
the first time that alterations in the hepatic LDL-R,
CYP7a-1 and HMG-CoA expression at least in part
appear to underlie this effect. Our findings suggest that
FPS has the capacity to influence cholesterol handling at
multiple points in the metabolic process. Further studies
are needed to determine precisely where and how in the
various pathways monkshood protein influences expres-
sion of the LDL receptor, CYP7a-1 and HMG-CoA reduc-
tase. The efficacy of this potential lipid lowering agent also
warrants investigation in humans.
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